Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MnH5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHnZPVBKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygbYM2OD1{Lki5[U0xPSEQvF2= M3PTS3NCVkeHUh?=
human AN3-CA cell M37pXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXz1fIp7UW6qaXLpeIlwdiCxZjDoeY1idiCDTkOtR2Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5yNTDuUS=> NGPIeYZUSU6JRWK=
human CGTH-W-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFAvODFibl2= MXjTRW5ITVJ?
human GDM-1 cell M2XBcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoW2TY5pcWKrdHnvckBw\iCqdX3hckBITE1vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwN{46QSCwTR?= MYDTRW5ITVJ?
human A204 cell NIXEWnFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVPJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEmuNFYhdk1? M17sO3NCVkeHUh?=
human G-402 cell M1PVW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUX2dok{UW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVU{OS56NDDuUS=> MVPTRW5ITVJ?
human MFE-296 cell NFPRZmpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkO3TY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkm2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42QTB{MjFOwG0> MXPTRW5ITVJ?
human NOS-1 cell NGHXfWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYXJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;MD62OVk5PyEQvF2= Ml3FV2FPT0WU
human KG-1 cell NWq0c5k2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlzCTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63NVc2PSEQvF2= NX\JSm1VW0GQR1XS
human HT55 cell MmS1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUTJcohq[mm2aX;uJI9nKGi3bXHuJGhVPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm4O|gyKM7:TR?= MmDHV2FPT0WU
human MG-63 cell MmnRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2TacmlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> NYe2UmVKW0GQR1XS
human CCF-STTG1 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlXJTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTFwMES5PFEh|ryP MX3TRW5ITVJ?
human RT-112 cell NWHZdm9HT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M13XcGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> NW[5TWxsW0GQR1XS
human MC-IXC cell NGDpUnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NE\QR2pKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOTF3MUKg{txO MnWyV2FPT0WU
human HUTU-80 cell M2Owdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI5OTB|IN88US=> M3PQdnNCVkeHUh?=
human MV-4-11 cell MnrpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4DNd2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO MY\TRW5ITVJ?
human LCLC-103H cell M1PpVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mny0TY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? NInGO3RUSU6JRWK=
human G-401 cell NV3UVoR1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHvVUpBKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> MkPTV2FPT0WU
human A704 cell NXHVXotIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3yyd2lvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN MVvTRW5ITVJ?
human ESS-1 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1vrPGlvcGmkaYTpc44hd2ZiaIXtZY4hTVOVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxOzl4IN88US=> M1;3Z3NCVkeHUh?=
human HLE cell NGfDXpNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVexd4RuUW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY{QDB2IN88US=> NGXGTpBUSU6JRWK=
human NY cell M4HlTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\6cZFKdmirYnn0bY9vKG:oIHj1cYFvKE6\IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT64OFgzOSEQvF2= MmTSV2FPT0WU
human A427 cell M1OyUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm4NFc2KM7:TR?= NXH4WllqW0GQR1XS
human SK-N-DZ cell M{exbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLHUG5KdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? MkezV2FPT0WU
human J82 cell MlP1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1v6eGlvcGmkaYTpc44hd2ZiaIXtZY4hUjh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj6wOlA5QCEQvF2= MlHQV2FPT0WU
human GI-1 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\tfGlvcGmkaYTpc44hd2ZiaIXtZY4hT0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlI6PTFizszN NYLCZXN4W0GQR1XS
human NCI-H716 cell MmHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGTW[ZNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IO|E3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5|MU[zN{DPxE1? MUjTRW5ITVJ?
human SF126 cell M4nqNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF\ycmRKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41PzR3OTFOwG0> NVKzO3A3W0GQR1XS
human H4 cell NGTHXJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4TvT2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxNlYzKM7:TR?= MVvTRW5ITVJ?
human LB831-BLC cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmn1TY5pcWKrdHnvckBw\iCqdX3hckBNSjh|MT3CUGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2NU[2JO69VQ>? NWXEXm1DW0GQR1XS
human HCC1395 cell NGjrSHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXPKNINQUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? NYWzcnNkW0GQR1XS
human LK-2 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGxMNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[0OVY6KM7:TR?= MWHTRW5ITVJ?
human G-361 cell MoTrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2fJemlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA1ODh{IN88US=> NF7VOIlUSU6JRWK=
human NCI-H2342 cell M{X0TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFq3[JdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlM1OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LjDJR|UxRTNwMUOzNVYh|ryP MoLBV2FPT0WU
human SK-LU-1 cell  NEjKVmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MknHTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yQDd4NzFOwG0> MVjTRW5ITVJ?
human IGROV-1 cell  NF:zbZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlI1PzF|IN88US=> M3nRR3NCVkeHUh?=
human EB2 cell NELS[3RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP MWPTRW5ITVJ?
human CAL-54 cell MmHZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWfJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlg{PjdizszN NXPaZm82W0GQR1XS
human LB1047-RCC cell MnPUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUf0R21rUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjN|MUO2PEDPxE1? MlLlV2FPT0WU
Daudi cell MlnZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHBTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53M{G2OEDPxE1? M37FWHNCVkeHUh?=
human Daudi cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGRifWSrIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz62OlIyQSEQvF2= MkXGV2FPT0WU
human A172 cell NUjsZ4lLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVrRUnNFUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44Ozd7IN88US=> NFvoXmFUSU6JRWK=
human KGN cell NGnNeGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYqwTmFwUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA3PzB7IN88US=> NEHKOI1USU6JRWK=
human SNG-M cell M{\WZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHO0[5lKdmirYnn0bY9vKG:oIHj1cYFvKFOQRz3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDZ4OTFOwG0> NH3vS|RUSU6JRWK=
human SW1710 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3vC[2lvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzNzODFOwG0> M3jRb3NCVkeHUh?=
human HT29 cells NIPDU4hRem:uaX\ldoF1cW:wIHHzd4F6 Mn7VRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv M37kblE5PjJyM{iy
human A375P cells M1PkWnBzd2yrZnXyZZRqd25iYYPzZZk> Mn:5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1VEBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= M3zkRlE5PjJyM{iy
human HN5 cells Mmi4VJJwdGmoZYLheIlwdiCjc4PhfS=> NFjsT3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= MUKxPFYzODN6Mh?=
HUVEC MoXuSpVv[3Srb36gZZN{[Xl? MlnJNUDPxE1? NEHNcoI3KGh? MWLBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3YnWg[o9zdWG2aX;uJIF1KDBwMTD1UUBi\nSncjC2JIhzeyCkeTDNZZRzcWenbDDhd5NigQ>? M3XUWVI1ODN4MESy
human Daoy cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYmwO5d2UW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44Pzl2OTFOwG0> NX\uTXRUW0GQR1XS
human DMS-273 cell Ml;sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmnZTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46PjJyMjFOwG0> NVHNVplLW0GQR1XS
human KU812 cell NFmzR5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGtWQDF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6zO|gyOiEQvF2= MnP3V2FPT0WU
human NCI-H727 cell NWDNToUyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41ODlyMTFOwG0> M1rJXXNCVkeHUh?=
human P30-OHK cell MnjHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYS3fohmUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52Nkm0JO69VQ>? MWnTRW5ITVJ?
human MIA-PaCa-2 cell M{PR[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGX0SnRKdmirYnn0bY9vKG:oIHj1cYFvKE2LQT3QZWNiNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[wOFY3KM7:TR?= M2n4[nNCVkeHUh?=
human TT cell NIG4bWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJHRVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54NkK0JO69VQ>? NGHyVpNUSU6JRWK=
human DK-MG cell NX[zV29{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmTKTY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt NIn5bHNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID